Viewray, Inc.

    • Moat Score
    • Safety Score
    • Market Cap $1.82K
    • PE -0
    • Debt $73.48M
    • Cash $85.53M
    • EV -$12.05M
    • FCF -$116.78M

    Earnings

    loading chart...

    Sales & Net Margins

    loading chart...
    Earnings-$110.42M
    EBIT-$110.21M
    ROE-200%
    ROA-47%
    FCF-$116.78M
    Equity$55.26M
    Growth Stability1
    PE-0
    PB0
    P/FCF-0
    P/S0
    Price/Cash46.92K
    Debt/Equity1.33
    Debt/FCF-0.63
    Net Margins-128%
    Gross Margins8%
    Op. Margins-104%
    Sales Growth YoY19%
    Sales Growth QoQ-35%
    Sales CAGR32%
    Equity CAGR22%
    Earnings Growth YoY12%
    Earnings Growth QoQ4%
    Sales CAGR 5Y1%
    Equity CAGR 5Y-4%
    Earnings CAGR 3Y25%
    Sales CAGR 3Y25%
    Equity CAGR 3Y-25%
    Market Cap$1.82K
    Revenue$105.86M
    Assets$233.16M
    Total Debt$73.48M
    Cash$85.53M
    Shares Outstanding182.31M
    EV-12.05M
    Moat Score1%
    Safety Score61%
    Working Capital26.8M
    Current Ratio1.16
    Gross Profit$8.52M
    Shares Growth 3y9%
    Equity Growth QoQ-33%
    Equity Growth YoY-63%

    Assets & ROA

    loading chart...

    Stockholders Equity & ROE

    loading chart...
    ViewRay Inc is a radiation therapy and imaging technology company. It designs, manufactures and markets radiation therapy systems that provide real-time imaging during radiation treatment. Its product portfolio encompasses The MRIdian linac system, The MRIdian system, the Monte Carlo treatment planning system, etc. The company holds the license for its combination of MRI and radiation therapy technologies.

    SEC Filings

    Direct access to Viewray, Inc. (VRAYQ) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

    • 2023
      • 10-Q Mar 31
    • 2022
      • 10-K Dec 31
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-Q Mar 31
    • 2021
      • 10-K Dec 31
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-Q Mar 31

    Sector Comparison

    How does Viewray, Inc. compare to its competitors?

    Not enough data to generate a comparison chart between Viewray, Inc. and its competitors. Please check back later.

    Peter Lynch's Chart

    This chart shows the current pricing of Viewray, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

    loading chart...

    Viewray, Inc. Discounted Cash Flow

    Fully customizable DCF calculator online for Viewray, Inc..

    = -$1.2B
    012345678910TV
    fcf-$117M-$117M-$117M-$117M-$117M-$117M-$117M-$117M-$117M-$117M-$117M-$1.2B
    DCF-$106M-$97M-$88M-$80M-$73M-$66M-$60M-$54M-$50M-$45M-$450M
    Value-$1.2B

    Competitiveness and MOAT

    High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

    Years12/201412/201512/201612/201712/201812/201912/202012/202112/2022TTM
    Net Margins-528%-433%-228%-212%-94%-137%-189%-157%-105%-128%
    ROA--79%-91%-35%-25%-34%-41%-32%-39%-47%
    ROE-647%116%-4K%-46%-56%-83%-65%-131%-200%

    Safety and Stability

    Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

    Years12/201412/201512/201612/201712/201812/201912/202012/202112/2022TTM
    Debt over FCF--0.66-1.26-0.62-0.44-0.64-0.82-0.9-0.77-0.63
    Debt over Equity-0.1-4.17-1.0122.40.330.260.440.340.891.33
    Growth Stability---------1

    Growth

    Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

    Years12/201412/201512/201612/201712/201812/201912/202012/202112/2022CAGR 5Y
    Revenue YoY growth-62%114%53%138%8%-35%23%46%1%
    Earnings YoY growth-33%13%43%6%57%-10%2%-2%-
    Equity YoY growth--95%527%-105%8K%29%-40%30%-52%-4%
    FCF YoY growth-49%-20%105%74%-31%-20%-9%50%-